Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immunosequencing of the T-cell receptor repertoire reveals signatures specific for diagnosis and characterization of early Lyme disease

Julia Greissl, Mitch Pesesky, Sudeb C. Dalai, Alison W. Rebman, Mark J. Soloski, Elizabeth J. Horn, Jennifer N. Dines, Rachel M. Gittelman, Thomas M. Snyder, Ryan O. Emerson, Edward Meeds, Thomas Manley, Ian M. Kaplan, Lance Baldo, Jonathan M. Carlson, Harlan S. Robins, John N. Aucott
doi: https://doi.org/10.1101/2021.07.30.21261353
Julia Greissl
aMicrosoft Research, Redmond, Washington, USA, and Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitch Pesesky
bAdaptive Biotechnologies, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sudeb C. Dalai
bAdaptive Biotechnologies, Seattle, Washington, USA
cStanford University School of Medicine, Stanford, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alison W. Rebman
dLyme Disease Research Center, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J. Soloski
dLyme Disease Research Center, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth J. Horn
eLyme Disease Biobank, Portland, Oregon, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer N. Dines
bAdaptive Biotechnologies, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel M. Gittelman
bAdaptive Biotechnologies, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas M. Snyder
bAdaptive Biotechnologies, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan O. Emerson
bAdaptive Biotechnologies, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward Meeds
aMicrosoft Research, Redmond, Washington, USA, and Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Manley
bAdaptive Biotechnologies, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian M. Kaplan
bAdaptive Biotechnologies, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lance Baldo
bAdaptive Biotechnologies, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan M. Carlson
aMicrosoft Research, Redmond, Washington, USA, and Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harlan S. Robins
bAdaptive Biotechnologies, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John N. Aucott
dLyme Disease Research Center, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jaucott2@jhmi.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Lyme disease, the most common tick-borne illness in the United States, is most frequently caused by infection with Borrelia burgdorferi. Although early antibiotic treatment can prevent development of severe illness and late manifestations, diagnosis is challenging in patients who do not present with a typical erythema migrans rash. To support a diagnosis of Lyme disease in such cases, guidelines recommend 2-tiered serologic testing. However, 2-tiered testing has numerous limitations, including ambiguity in interpretation and lower sensitivity in early disease. We developed a diagnostic approach for Lyme disease based on the T-cell response to B. burgdorferi infection by immunosequencing T-cell receptor (TCR) repertoires in blood samples from 3 independent cohorts of patients with laboratory-confirmed or clinically diagnosed early Lyme disease, as well as endemic and non-endemic controls. We identified 251 public, Lyme-associated TCRs that were used to train a classifier for detection of early Lyme disease with 99% specificity. In a validation cohort of individuals with early Lyme disease, TCR testing demonstrated a 1.9-fold increase in sensitivity compared to standard 2-tiered testing (STTT; 56% versus 30%), with a 3.1-fold increase ≤4 days from the onset of symptoms (44% versus 14%). TCR positivity predicted subsequent seroconversion in 37% of initially STTT-negative patients, suggesting that the T-cell response is detectable before the humoral response. While positivity for both tests declined after treatment, greater declines in posttreatment sensitivity were observed for STTT compared to TCR testing. Higher TCR scores were associated with clinical measures of disease severity, including abnormal liver function test results, disseminated rash, and number of symptoms. A subset of Lyme-associated TCRs mapped to B. burgdorferi antigens, demonstrating high specificity of a TCR immunosequencing approach. These results support the clinical utility of T-cell‒based testing as a sensitive and specific diagnostic for early Lyme disease, particularly in the initial days of illness.

Competing Interest Statement

M.P., J.N.D., R.M.G., T.M.S., and I.M.K. declare employment and equity ownership in Adaptive Biotechnologies. S.C.D. declares employment with Adaptive Biotechnologies and Stanford University School of Medicine, and equity ownership in Adaptive Biotechnologies. A.W.R. declares institutional support from the Steven and Alexandra Cohen Foundation, and Global Lyme Alliance. M.J.S. declares institutional support from the Steven and Alexandra Cohen Foundation, and NIH grant P30 AR070254. E.J.H. declares compensation from the Lyme Disease Biobank and institutional support from Bay Area Lyme Foundation, the Steven and Alexandra Cohen Foundation, and Adaptive Biotechnologies. R.O.E. and T.M. declare employment with Adaptive Biotechnologies during the time of this research. L.B. and H.S.R. declare employment, equity ownership and leadership with Adaptive Biotechnologies. J.N.A. declares consulting with Tarsus Pharmaceuticals and Pfizer; participation in an advisory board with Adaptive Biotechnologies; expert testimony; membership on the Bay Area Lyme Foundation Scientific Advisory Board; Past Chair, 2018, HHS Tick-borne Disease Working Group, Office of HIV/AIDS and Infectious Disease Policy, Office of the Assistant Secretary of Health, Department of Health and Human Services; and institutional support from the Steven and Alexandra Cohen Foundation and Global Lyme Alliance.

Funding Statement

This study was funded by Adaptive Biotechnologies, who also funded medical writing and editorial support provided by Melanie Styers of BluPrint Oncology Concepts and Kristin MacIntosh of Adaptive Biotechnologies.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All procedures involving human participants were conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. For the Lyme Disease Biobank (LDB) cohort, Institutional review board (IRB) approval was obtained for each site through the LDB sponsor protocol (Advarra IRB) or institution-specific IRB. For the Boca Biolistics cohort, IRB approval was obtained through Advarra IRB. Human subjects protocols for the JHU cohort were approved by the IRBs of Johns Hopkins University and Stanford University. All participants provided written informed consent prior to enrollment.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data requests may be submitted for consideration to Adaptive Biotechnologies Medical Information (https://www.adaptivebiotech.com/medical-information-request/).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 02, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immunosequencing of the T-cell receptor repertoire reveals signatures specific for diagnosis and characterization of early Lyme disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immunosequencing of the T-cell receptor repertoire reveals signatures specific for diagnosis and characterization of early Lyme disease
Julia Greissl, Mitch Pesesky, Sudeb C. Dalai, Alison W. Rebman, Mark J. Soloski, Elizabeth J. Horn, Jennifer N. Dines, Rachel M. Gittelman, Thomas M. Snyder, Ryan O. Emerson, Edward Meeds, Thomas Manley, Ian M. Kaplan, Lance Baldo, Jonathan M. Carlson, Harlan S. Robins, John N. Aucott
medRxiv 2021.07.30.21261353; doi: https://doi.org/10.1101/2021.07.30.21261353
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Immunosequencing of the T-cell receptor repertoire reveals signatures specific for diagnosis and characterization of early Lyme disease
Julia Greissl, Mitch Pesesky, Sudeb C. Dalai, Alison W. Rebman, Mark J. Soloski, Elizabeth J. Horn, Jennifer N. Dines, Rachel M. Gittelman, Thomas M. Snyder, Ryan O. Emerson, Edward Meeds, Thomas Manley, Ian M. Kaplan, Lance Baldo, Jonathan M. Carlson, Harlan S. Robins, John N. Aucott
medRxiv 2021.07.30.21261353; doi: https://doi.org/10.1101/2021.07.30.21261353

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (559)
  • Anesthesia (135)
  • Cardiovascular Medicine (1774)
  • Dentistry and Oral Medicine (239)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10826)
  • Forensic Medicine (8)
  • Gastroenterology (595)
  • Genetic and Genomic Medicine (2963)
  • Geriatric Medicine (289)
  • Health Economics (534)
  • Health Informatics (1935)
  • Health Policy (836)
  • Health Systems and Quality Improvement (746)
  • Hematology (294)
  • HIV/AIDS (634)
  • Infectious Diseases (except HIV/AIDS) (12530)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (89)
  • Nephrology (325)
  • Neurology (2815)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (600)
  • Oncology (1475)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (258)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (869)
  • Pharmacology and Therapeutics (368)
  • Primary Care Research (340)
  • Psychiatry and Clinical Psychology (2650)
  • Public and Global Health (5387)
  • Radiology and Imaging (1019)
  • Rehabilitation Medicine and Physical Therapy (598)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (293)
  • Sports Medicine (279)
  • Surgery (328)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (127)